Global Coagulation Testing Market Size, Share, Opportunities, And Trends By Test Type (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Platelet Function Tests, Other), By End Users (Hospitals And Clinics, Diagnostic Centres, Ambulatory Care Centres), And By Geography - Forecasts From 2024 To 2029

  • Published : May 2024
  • Report Code : KSI061611699
  • Pages : 123

The Coagulation Testing market was valued at US$2,972.150 million in 2022 and is expected to increase at a CAGR of 3.84% over the forecast period to reach a total market size of US$3,868.871 million by 2029.

Coagulation tests are conducted to test the hemostasis system. Generally, this test is performed with a coagulometer, which measures and evaluates the rate at which clots form or blood coagulates. A blood clot in a blood vessel can lead to a heart attack, thrombosis, or embolism. By performing these tests, one can avoid these unfavorable outcomes. 

A growing prevalence of blood disorders and cardiovascular conditions, an increase in the geriatric population, surging demand for point-of-care (POC) coagulation testing, and technological advancements such as faster and easier-to-use devices with advanced sensors have been contributing to the market growth.  

The introduction of new coagulation analyzer tests and rapid advancements in technology have led to an increase in the quality and efficiency of hemostasis laboratories over the past decade. To prevent bleeding and excessive coagulation, the liver plays an essential role in hemostasis. The CN-6000 and CN-3000 are fully automated, next-generation blood coagulation analyzers recently launched by Sysmex in the EMEA region. As part of the CN-6000 and CN-3000, which were recently introduced, four new capabilities have been built to cater to the increasingly diverse needs of high-volume hemostasis testing. 

Market Drivers:

  • Rising population is predicted to propel the global market of coagulation testing expansion.

There is an increase in the population of the world which will correlate with increasing healthcare requirement as there will be more incidences of diseases and medical condition including coagulation disorders, according to the United Nations (UN) data on World Population Prospects, the world's population reached 8 billion in November 2022, marking a significant milestone in human development, it expected to reach 9 billion by 2037 while the population is expected to increase by nearly 2 billion in the next 30 years, reaching 9.7 billion in 2050. 

China and India remain the two most populous countries, with each representing nearly 18 percent of the world's population both with more than 1 billion individual. In April 2023, India's population was expected to extent to 1,425,775,850 people, surpassing that of mainland China. 

  • Increased prevalence of liver disease is expected to surge the market growth.

As the liver is a central player within the clotting process, thus, acute and chronic liver illness regularly leads to coagulation disorders due to a few variables,like decreased amalgamation of clotting and inhibitor factors, an failure to eliminate activated variables, and defects in both amount and quality of platelets. As per American Liver Foundation information from September 2023, more over hundred million U.S. adult individuals suffer from liver disease, with 4.5 million analyzed for it. People with untreated liver disease can lead to liver failure and cancer, with 80-100 million adult people possibly suffering from fatty liver disease and ignorant about it themselves.

  • In addition, as per Centers for Disease and Control and Prevention information of November 2022 Liver cancer influences 25,000 men and 11,000 women within the United States every year, with 19,000 dying from the same.

Moreover, according to British Liver Trust, over 10,000 deaths due to liver disease happen every year within the UK, with a four-fold increment over the past fifty years. In 2022, England had about 9,770 deaths, Northern Ireland had 369, Scotland had 1,237, and Ridges had 701 deaths in total while the UK-wide death number was 12,077. Liver disease is connected to deprivation as well as inequality, with untimely passings being four times higher in deprived regions compared to affluent areas in both Scotland and England.  In light of the dominant rate of liver disease globally, the coagulation testing industry will expand at an increasing rate amid the estimate period.

  • Improvements in the Healthcare Sector are anticipated to boost the demand of coagulation testing globally.

The increasing commerce of blood coagulation analyzers have driven to a surge within the advancement of cutting-edge therapeutic facilities, labs, treatment centers, and research organizations. All through the forecasted period, these variables are anticipated to impel market extension. Innovative technological headways in blood coagulation testing have made the method simpler, more detailed, and precise.

Rising obesity rates necessitate extensive testing for blood sugar levels, leading to a massive growth in the demand for blood coagulation analyzers. The increasing population of cardiovascular illnesses and blood disorders is driving market growth, as severe blood-related illnesses can be costly to treat. The geriatric population's growth is also contributing to the market size.

Market Restraints:

  • The high cost of an automated coagulation system could hinder the market growth.

Having a fully automated coagulation system comes at a high cost. Staff members other than hematologists must obtain training and be competent. It is more difficult to establish rigorous quality assurance standards outside the laboratory.  Stringent regulations governing coagulation testing devices, the high cost of fully automatic hemostasis equipment, and the concern over the potential side effects of blood testing are inhibiting the growth of the global market. In addition, the slow adoption of advanced hemostasis instruments and the lack of awareness regarding innovative and advanced applications of coagulation test devices are also hampering the market growth, particularly in developing countries

Key Developments:

  • May 2023- Siemens Healthineers introduced the Atellica HEMA 570 and 580 Analyzers, which offer next-gen hematology analyzers with integrated automation and intelligence. These analyzers aim to eliminate workflow barriers and achieve fast throughput in high-volume hematology testing. The Atellica HEMA 570 Analyzer and Atellica HEMA 580 Analyzer are designed to provide intuitive interfaces and multi-analyzer automation connectivity, enabling physicians to deliver critical hematology information reliably. Conventionally, hematology testing is complex and time-sensitive, requiring experienced staff to evaluate results. The Atellica HEMA 570 and 580 Analyzers aim to break down these barriers, enabling faster patient results and improved workflow efficiency.
  • March 2023- Sysmex Corporation and Siemens Healthcare Diagnostics signed a global OEM agreement to supply hemostasis instruments and reagents as OEMs. The agreement allowed both companies to distribute their combined portfolio of hemostasis instruments and reagents under their respective brands, along with their wider products and services. The collaboration aims to diversify customer needs by offering effective solutions to laboratories worldwide. Sysmex and Siemens Healthineers gave hemostasis items utilized in blood clotting disorders testing, preoperative bleeding risk management, and observing patients getting anticoagulant treatment medicines.
  • July 2022- HORIBA Medical displayed its Yumizen G range of hemostasis reagents and analyzers at ISTH 2022 Congress. The company introduced its new generation Yumizen G800 and G1550 automated analyzers, as well as ready-to-use reagents for blood coagulation tests. The Yumizen G hemostasis product range supports high-quality and cost-effective screening and assessment of bleeding disorders. The new-generation analyzers are designed for managing coagulation, thrombophilia diagnostics, and monitoring requirements in clinical laboratories with mid to high workloads. The Yumizen G systems use only one cuvette per test to avoid waste and overconsumption.

Segmentation:

Global Coagulation Testing Market is segmented and analyzed as below:

  • By Test Type
    • Prothrombin Time Testing
    • Fibrinogen Testing
    • Activated Clotting Time Testing
    • Platelet Function Tests
    • Other 
  • By End Users
    • Hospitals and Clinics
    • Diagnostic Centres
    • Ambulatory Care Centres 
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • France
      • Others
    • Middle East and Africa (MEA)
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • China
      • India
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Japan
      • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. GLOBAL COAGULATION TESTING MARKET BY TEST TYPE

5.1. Introduction

5.2. Prothrombin Time Testing

5.2.1. Market Opportunities and Trends

5.2.2. Growth Prospects

5.2.3. Geographic Lucrativeness

5.3. Fibrinogen Testing

5.3.1. Market Opportunities and Trends

5.3.2. Growth Prospects

5.3.3. Geographic Lucrativeness

5.4. Activated Clotting Time Testing

5.4.1. Market Opportunities and Trends

5.4.2. Growth Prospects

5.4.3. Geographic Lucrativeness

5.5. Platelet Function Tests

5.5.1. Market Opportunities and Trends

5.5.2. Growth Prospects

5.5.3. Geographic Lucrativeness

5.6. Other 

5.6.1. Market Opportunities and Trends

5.6.2. Growth Prospects

5.6.3. Geographic Lucrativeness

6. GLOBAL COAGULATION TESTING MARKET BY END USERS

6.1. Introduction

6.2. Hospitals and Clinics

6.2.1. Market Opportunities and Trends

6.2.2. Growth Prospects

6.2.3. Geographic Lucrativeness

6.3. Diagnostic Centres

6.3.1. Market Opportunities and Trends

6.3.2. Growth Prospects

6.3.3. Geographic Lucrativeness

6.4. Ambulatory Care Centres 

6.4.1. Market Opportunities and Trends

6.4.2. Growth Prospects

6.4.3. Geographic Lucrativeness

7. GLOBAL COAGULATION TESTING MARKET BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. By Test Type

7.2.2. By End Users

7.2.3. By Country

7.2.3.1. United States

7.2.3.1.1. Market Opportunities and Trends

7.2.3.1.2. Growth Prospects

7.2.3.2. Canada

7.2.3.2.1. Market Opportunities and Trends

7.2.3.2.2. Growth Prospects

7.2.3.3. Mexico

7.2.3.3.1. Market Opportunities and Trends

7.2.3.3.2. Growth Prospects

7.3. South America

7.3.1. By Test Type

7.3.2. By End Users

7.3.3. By Country 

7.3.3.1. Brazil

7.3.3.1.1. Market Opportunities and Trends

7.3.3.1.2. Growth Prospects

7.3.3.2. Argentina

7.3.3.2.1. Market Opportunities and Trends

7.3.3.2.2. Growth Prospects

7.3.3.3. Others

7.3.3.3.1. Market Opportunities and Trends

7.3.3.3.2. Growth Prospects

7.4. Europe

7.4.1. By Test Type

7.4.2. By End Users

7.4.3. By Country

7.4.3.1. UK

7.4.3.1.1. Market Opportunities and Trends

7.4.3.1.2. Growth Prospects

7.4.3.2. Germany

7.4.3.2.1. Market Opportunities and Trends

7.4.3.2.2. Growth Prospects

7.4.3.3. France

7.4.3.3.1. Market Opportunities and Trends

7.4.3.3.2. Growth Prospects

7.4.3.4. Others

7.4.3.4.1. Market Opportunities and Trends

7.4.3.4.2. Growth Prospects

7.5. Middle East and Africa

7.5.1. By Test Type

7.5.2. By End Users

7.5.3. By Country

7.5.3.1. Saudi Arabia

7.5.3.1.1. Market Opportunities and Trends

7.5.3.1.2. Growth Prospects

7.5.3.2. UAE

7.5.3.2.1. Market Opportunities and Trends

7.5.3.2.2. Growth Prospects

7.5.3.3. Israel

7.5.3.3.1. Market Opportunities and Trends

7.5.3.3.2. Growth Prospects

7.5.3.4. Others

7.5.3.4.1. Market Opportunities and Trends

7.5.3.4.2. Growth Prospects

7.6. Asia Pacific

7.6.1. By Test Type

7.6.2. By End Users

7.6.3. By Country

7.6.3.1. China

7.6.3.1.1. Market Opportunities and Trends

7.6.3.1.2. Growth Prospects

7.6.3.2. India

7.6.3.2.1. Market Opportunities and Trends

7.6.3.2.2. Growth Prospects

7.6.3.3. South Korea

7.6.3.3.1. Market Opportunities and Trends

7.6.3.3.2. Growth Prospects

7.6.3.4. Taiwan

7.6.3.4.1. Market Opportunities and Trends

7.6.3.4.2. Growth Prospects

7.6.3.5. Thailand

7.6.3.5.1. Market Opportunities and Trends

7.6.3.5.2. Growth Prospects

7.6.3.6. Indonesia

7.6.3.6.1. Market Opportunities and Trends

7.6.3.6.2. Growth Prospects

7.6.3.7. Japan

7.6.3.7.1. Market Opportunities and Trends

7.6.3.7.2. Growth Prospects

7.6.3.8. Others

7.6.3.8.1. Market Opportunities and Trends

7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. Abbott

9.2. Diagnostica Stago, S.A.S.

9.3. F. Hoffmann-La Roche Ltd

9.4. Thermo Fisher Scientific

9.5. Enzyme Research Laboratories Ltd

9.6. Sekisui Medical Co., Ltd.

9.7. Stago Group

9.8. Coagulation Sciences LLC

9.9. RUSNANO Group

9.10. Universal Biosensors


Abbott

Diagnostica Stago, S.A.S.

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific

Enzyme Research Laboratories Ltd

Sekisui Medical Co., Ltd.

Stago Group

Coagulation Sciences LLC

RUSNANO Group

Universal Biosensors